Major Investor Group's Stake Diluted to 29.3% Following Company Offerings
SRZN has more than doubled off its 52-week low of $5.9.
Summary
The Column Group III, a major investor group including a company director, reported a diluted ownership stake of 29.3% in Surrozen, Inc., reflecting the impact of recent company share issuances.
Key Events · Ownership and Investor Activity · SRZN
-
Major Shareholder Update
The Column Group III entities, including director Tim Kutzkey, now beneficially own 3,824,612 shares, representing 29.3% of Surrozen's common stock.
-
Dilution from Company Offerings
The decrease in percentage ownership is attributed to dilution from the company's recent capital raising activities, including a $200 million shelf offering and a $50 million At-The-Market program launched in March 2026.
-
Significant Stake Maintained
Despite the dilution, the group's holding remains substantial, valued at approximately $107.7 million based on the current stock price.
Analysis · SRZN · Life Sciences
This Schedule 13D/A updates the beneficial ownership of The Column Group III entities, including director Tim Kutzkey, to 29.3% of Surrozen's common stock. The filing explicitly states this percentage decrease is due to dilution from the company's recent sales of additional shares, such as the $200 million shelf offering and $50 million ATM program initiated in March 2026. While the group remains a significant shareholder, their relative influence has been reduced by these capital raises.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.9% of the 1668 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SRZN was trading at $28.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $326.8M. The 52-week trading range was $5.90 to $35.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.